These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31945774)

  • 1. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe.
    Armuzzi A; DiBonaventura MD; Tarallo M; Lucas J; Bluff D; Hoskin B; Bargo D; Cappelleri JC; Quirk D; Salese L
    PLoS One; 2020; 15(1):e0227914. PubMed ID: 31945774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab.
    Favale A; Onali S; Caprioli F; Pugliese D; Armuzzi A; Macaluso FS; Orlando A; Viola A; Fries W; Rispo A; Castiglione F; Mocci G; Chicco F; Usai P; Calabrese E; Biancone L; Monteleone G; Fantini MC;
    Inflamm Bowel Dis; 2019 Oct; 25(11):1805-1812. PubMed ID: 30931477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe.
    Armuzzi A; Tarallo M; Lucas J; Bluff D; Hoskin B; Bargo D; Cappelleri JC; Salese L; daCosta DiBonaventura M
    BMC Gastroenterol; 2020 Jan; 20(1):18. PubMed ID: 31964359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ulcerative Colitis Treatment Patterns and Cost of Care.
    Null KD; Xu Y; Pasquale MK; Su C; Marren A; Harnett J; Mardekian J; Manuchehri A; Healey P
    Value Health; 2017 Jun; 20(6):752-761. PubMed ID: 28577692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients.
    Kamal ME; Werida RH; Radwan MA; Askar SR; Omran GA; El-Mohamdy MA; Hagag RS
    Inflammopharmacology; 2024 Oct; 32(5):3259-3269. PubMed ID: 38985232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
    Sandborn WJ; Sakuraba A; Wang A; Macaulay D; Reichmann W; Wang S; Chao J; Skup M
    Curr Med Res Opin; 2016 Jul; 32(7):1233-41. PubMed ID: 26986449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Aliment Pharmacol Ther; 2016 May; 43(9):994-1003. PubMed ID: 26991059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study.
    Han M; Jung YS; Cheon JH; Park S
    Yonsei Med J; 2020 Jan; 61(1):48-55. PubMed ID: 31887799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.
    Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Savova G; Churchill S; Karlson EW; Kohane I; Liao KP; Murphy SN
    Inflamm Bowel Dis; 2016 Apr; 22(4):880-5. PubMed ID: 26933751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States.
    Milev S; DiBonaventura MD; Quon P; Wern Goh J; Bourret J; Peeples-Lamirande K; Soonasra A; Cappelleri JC; Quirk D
    J Med Econ; 2019 Sep; 22(9):859-868. PubMed ID: 31012362
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study.
    Viola A; Pugliese D; Renna S; Furfaro F; Caprioli F; D'Incà R; Bossa F; Mazza S; Costantino G; Fantini MC; Fiorino G; Alibrandi A; Orlando A; Armuzzi A; Fries W
    Dig Liver Dis; 2019 Apr; 51(4):510-515. PubMed ID: 30472389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases.
    Sah J; Teeple A; Muser E; Gutierrez C; Dassopoulos T
    Curr Med Res Opin; 2022 Jul; 38(7):1093-1101. PubMed ID: 35475385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis.
    Long MD; Cohen RD; Smith TW; DiBonaventura M; Gruben D; Bargo D; Salese L; Quirk D
    Dig Dis; 2022; 40(5):553-564. PubMed ID: 34879378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis: A Real-life Experience from the SIGENP-IBD Registry.
    Aloi M; Bramuzzo M; Arrigo S; Romano C; D'Arcangelo G; Lacorte D; Gatti S; Illiceto MT; Zucconi F; Dilillo D; Zuin G; Knafelz D; Ravelli A; Cucchiara S; Alvisi P;
    J Pediatr Gastroenterol Nutr; 2018 Jun; 66(6):920-925. PubMed ID: 29315163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of biologics in pediatric inflammatory boweldisease: Real-life data from the Sicilian Network.
    Romeo AC; Ventimiglia M; Dipasquale V; Orlando A; Citrano M; Pellegrino S; Accomando S; Cottone M; Romano C
    Clin Res Hepatol Gastroenterol; 2020 Apr; 44(2):223-229. PubMed ID: 31204314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
    Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
    Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom.
    Lindsay JO; Picker N; Kromer D; Smyth M; Patel H
    Curr Med Res Opin; 2023 May; 39(5):681-689. PubMed ID: 36951899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease.
    Brady JE; Stott-Miller M; Mu G; Perera S
    Clin Ther; 2018 Sep; 40(9):1509-1521.e5. PubMed ID: 30126706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.